Pages
Related News
18Dec
Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders
0 CommentsCollaboration with funding of development activities gives Boehringer Ingelheim exclusive option to purchase certain Autifony assets to treat serious CNS... Read More →
10Jul
Autifony Therapeutics receives Orphan Drug Designation for AUT00206 for Fragile X Syndrome
0 CommentsAutifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
18May
Autifony Therapeutics initiates recruitment into schizophrenia clinical trial for first-in-class drug
0 CommentsAutifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
15Mar
Autifony Therapeutics obtains £1.3 million in funding from Innovate UK and the Dementia Discovery Fund to explore novel approach to treatment of dementia
0 CommentsAutifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
10Jan
Autifony Therapeutics announces positive results from Phase I study of AUT00206, a first-in-class Kv3 modulator for treatment of schizophrenia
0 CommentsAutifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
Tweets
Autifony is currently recruiting a Junior Medicinal Chemist, the position will be based in our lab in Stevenage, fo… https://t.co/PkP9TCxUcq
RT @BIODeutschland:Boehringer Ingelheim & Autifony Therapeutics collaborate on a novel therapeutic approach to a range of CNS disorder… https://t.co/sIz3B7CkOe
We have a very exciting announcement today! https://t.co/ofHB6LG3ZL
Comments are closed.